Cortigent Inc (CRGT) - Enterprise Value to EBITDA Ratio
Intellectual property protection via patents and strict FDA oversight create significant barriers to entry for Cortigent, Inc. (CRGT) competitors. Future growth depends on the success of trials for interfaces that restore vision and motor skills. This chart shows a market EV/EBITDA multiple of , confirming the efficiency of the fabless model, where device assembly is outsourced to US contractors to minimize infrastructure risks.
CRGT (cortigent.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization indicators:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
CRGT - Net Financial Result|Expected Profit Cortigent, Inc.|CRGT - Price to Earnings Multiple|Forward P/E Multiple Cortigent|CRGT - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio CRGT|CRGT - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Cortigent|CRGT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months cortigent.com|CRGT - Earnings per share increase in current year|Earnings growth forecast for next year Cortigent, Inc.
Fundamental company valuation:Cortigent Medical (CRGT)
The investment attractiveness of Cortigent, Inc. (CRGT) is based on the potential of neuromodulation interfaces, which require significant external funding. The EV/EBITDA metric compares the total enterprise value, including net debt, with operating profit before depreciation and amortization, revealing the real value of assets regardless of the tax regime. By analyzing the Cortigent, Inc. (CRGT) EV/EBITDA chart on the GURU.Markets platform, an investor can assess the startup's fundamental stability in the absence of commercial sales.
Competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Business Value to Operating Income Before Depreciation NBIX|RGC: Enterprise Value to EBITDA Ratio|axsome.com - Enterprise Value to Operating Income Before Depreciation Ratio|ACAD: EV/EBITDA Multiple|XENE - Total Company Value to Operating Income Before Depreciation Ratio|VKTX (Viking Pharma) - EV/EBITDA Multiple|SUPN - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple CPRX|DNLI - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN: Enterprise Value to Operating Income Before Depreciation|AMLX: Enterprise Value to EBITDA Ratio|Trevi Corp - Enterprise Value to Operating Income Before Depreciation Ratio|PRAX (Praxis Precision Medicines) - Enterprise Value to EBITDA Ratio|anavex.com - Business Value to Operating Income Before Depreciation|CBLL (CeriBell) - EV/EBITDA Multiple|Prothena Corporation PLC (PRTA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|Annexon Biosciences Inc. - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple OMER (Omeros)|NGNE - Enterprise Value to EBITDA Ratio|ACIU: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Voyager Therapeutics Inc VYGR|NMRA: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Scilex Holding Company, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tevogen Bio Holdings|ACOG: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CGTX|Inhibikase Therapeutics Inc (IKT) - Enterprise Value to EBITDA Multiple|Cassava - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ASRT (Assertio Holdings)|COYA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VTGN (Vistagen Therapeutics) - Enterprise Value to Operating Income Before Depreciation|OVID: EV/EBITDA Multiple|Company Value to EBITDA Acumen Pharmaceuticals Inc. (ABOS)|Enterprise Value to EBITDA Ratio CRVO|EV/EBITDA Multiple Alterity Therapeutics Ltd|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|PEPG (pepgen.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|Relmada Therapeutics Inc (RLMD) - Company Value to EBITDA|Annovis Bio Corp - EV/EBITDA Multiple|Grace Therapeutics, Inc. (GRCE) - Enterprise Value to EBITDA Ratio|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Klotho Neurosciences (KLTO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|RVPH: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio MTVA (MetaVia Inc)|Enterprise Value to Operating Income Before Depreciation Ratio NRXS|EV/EBITDA Multiple HSDT (Helius Medical Technologies)|Total Company Value to Operating Income Before Depreciation Ratio Passage Bio Inc. (PASG)|Neuphoria - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Minerva Neurosciences Inc (NERV)|ATHA: EV/EBITDA Multiple|Company Value to EBITDA Addex (ADXN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alzamend Neuro Inc.|Enterprise Value to Operating Income Before Depreciation CYCN (Cyclerion)|Enterprise Value to EBITDA Ratio PTIX (Protagenic Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio KTTA|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio chromocell.com CHRO|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation ITCI|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Marinus Pharma (MRNS)|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio neurobopharma.com|EV/EBITDA Multiple SAGE (Sage Therapeutics)|SNPX - Enterprise Value to EBITDA Ratio|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation VIGL (Vigil Neuroscience)|WENA: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple cerevel.com CERE
